Bibliography for the Drug Target Identification from Microbial Genomes

Bibliography
_________________________________________________________________________
Identification and Validation of Drug Targets
153
BIBLIOGRAPHY
. .
Adams, G. (2000). Lecture Notes, Microbiology, 29 Feb. 2000.
Akerley, B. J., Rubin, E. J., Camilli, A., Lampe, D. J., Robertson, H. M. and
Mekalanos, J. J. (1998). Systematic identification of essential genes by in
vitro mariner mutagenesis. Proc. Natl. Acad. Sci. USA., 95, 8927-8932.
Altschul S. F. (1990). Basic local alignment search tool. J. Mol. Biol., 215, 403-
410.
Anderson, A. A. (2003). Chemistry and Biology, 10, 787.
Aradi, I. and Erdi, P. (2006). Computational neuropharmacology, dynamical
approaches in drug discovery. Trends Pharmacol. Sci., 27, 240-243.
Arigoni, F., Talabot, F., Peitsch, M., Edgerton, M. D., Meldrum, E., Allet, E., Fish,
R., Jamotte, T., Curchod, M. L. and Loferer, H. (1998). A genome-based
approach for the identification of essential bacterial genes. Nat. Biotechnol.,
16, 851-856.
Aronov, A. M., Balakin, K. V., Kiselyov, A., Varma-O’Brien, S. and Ekins, S.
(2006). Applications of QSAR methods to ion channels. In, Ekins S (ed).
Computational Toxicology, Risk Assessment for Pharmaceutical and
Environmental Chemicals. John Wiley and Sons, Hoboken, NJ.

Bibliography
_________________________________________________________________________
154
Auckland, C., Teare, L., Cooke, F., Kaufmann, M. E., Warner, M., Jones, G.,
Bamford, K., Ayles, H., Johnson, A. P. (2002). J. Antimicrob. Chemother. ,
50, 743−746.
Badarinarayana, V., Estep, P. W., Shendure, J., Edwards, J., Tavazoie, S., Lam,
F. and Church, G. M. (2001). Selection analyses of insertional mutants
using subgenic-resolution arrays. Nat. Biotechnol., 19, 1060-1065.
Bairoch, A., Apweiler, R., Wu, C. H., Barker, W. C., Boeckmann, B., Ferro, S.,
Gasteiger, E., Huang, H., Lopez, R. and Magrane, M. (2005). The Universal
Protein Resource (UniProt). Nucleic Acids Res., 33, D154–D159.
Bajorath, J. (2002). Nat. Rev. Drug Discov., 1, 882-894.
Barbachyn, M. R., Brickner, S. J., Gadwood, R. C., Garmon, S. A., Grega, K. C.,
Hutchinson, D. K., Munesada, K., Reischer, R. J., Taniguchi, M.,
Thomasco, L. M., Toops, D. S., Yamada, H., Ford, C. W., and Zurenko, G.
E. (1998). Adv. Exp. Med. Biol., 456, 219−238.
Bartel, P. (1993). Elimination of false positives that arise in using the two-hybrid
system. Biotechniques, 14, 920-924.
Becker, O. M., Shacham, S., Marantz, Y. and Noiman, S. (2003). Curr. Opin. Drug
Discov. Devel. , 6, 353-361.
Becker, O. M., Shacham, S., Topf, M. and Naor, Z. (2000). World Patent, WO-
02_15106-A2.

Bibliography
_________________________________________________________________________
155
Beddell, C. R. (1976). Br. J. Pharmacol., 57, 201. [PMID, 938794].
Behr, M. A. (1999). Comparative genomics of BCG vaccines by whole-genome
DNA microarray. Science, 284, 1520-1523.
Benton, B. L., J. Ving, F. Malouin, P. K. Martin, M. B. Schmid, and D. Sun. March
(2000). Methods of screening for compounds active on Staphylococcus
aureus target genes. US Patent, 6, 37-123.
Benton, B. L., J. Ving, F. Malouin, P. K. Martin, M. B. Schmid, and D. Sun. (2001).
Methods of screening for compounds active on Staphylococcus aureus
target genes. US Patent, 6, 228, 588.
Berg, C. M. and Berg, D. A. (1996). Transposable element tools for microbial
genetics. In: Escherichia coli and Salmonella (Neidhardt F. C. ed. ), pp.
2588-2612.
Bernal, A., Ear, U. and Kyrpides N. (2001). Genomes OnLine Database (GOLD), a
monitor of genome projects world-wide. Nucleic Acids Res. , 29, 126-127.
Bernstein, F. C., Koetzle, T. F., Williams, T. F., Meyer, G. J. B., Jr, Brice, M. D.,
Rodgers, J. R., Kennard, O., Shimanouchi, T. and Tasumi, M. (1977). The
Protein Data Bank, A computer-based archival file for macromolecular
structures. J. Mol. Biol., 112, 535–542.

Bibliography
_________________________________________________________________________
156
Bissantz, C., Bernard, P., Hibert, M. and Rognan, D. (2003). Protein-based virtual
screening of chemical databases. II. Are homology models of G-protein
coupled receptors suitable targets? Proteins, 50, 5-25.
Blattner, F. R. (1997). The complete genome sequence of Escherichia coli K-12.
Science, 277, 1453-1462.
Block, P., Sotriffer, C. A., Dramburg, I. and Klebe, G. (2006). AffinDB, Afreely
accessible database of affinities for protein–ligand complexes from the
PDB. Nucleic Acids Res., 34, D522–D526.
Blundell, T. L. (1972). Adv. Protein Chem., 26, 279.
Blundell, T. L. (1996). Nature, 384, 23. [PMID, 8895597].
Bonacci, T. M., Mathews, J. L., Yuan, C., Lehmann, D. M., Malik, S. and Wu, D.
(2006). Differential targeting of Gbetagamma-subunit signaling with small
molecules. Science, 312, 443-446.
Brewerton, S. C., Dore, A. S., Drake, A. C., Leuther, K. K. and Blundell, T. L.
(2004). Structural analysis of DNA-PKcs, modelling of the repeat units
and insights into the detailed molecular architecture. J. Struct. Biol., 145,
295-306.
C. R. Beddell (1976), Br. J. Pharmacol., 57, 201 (1976). [PMID, 938794].
Cacace, A. (2003). Drug Discovery Today, 8, 785. [PMID, 12946641]
Campbell, S. F. (2000). Clin. Sci., 99, 255. [PMID, 10995589].

Bibliography
_________________________________________________________________________
157
Carper, S. W., Duffy, J. J. and Gerner, E. W. (1987). Cancer Res., 47, 5249-5255.
Cassell, G. H. and Mekalanos, J. (2001). JAMA, 285, 601−605.
Chalker, A. F., Minehart, H. W., Hughes, N. J., Koretke, K. K., Lonetto, M. A.,
Brinkman, K. K., Warren, P. V., Lupas, A., Stanhope, M. J., Brown, J. R.
and Hoffman, P. S. (2001). Systematic identification of selective essential
genes in Helicobacter pylori by genome prioritization and allelic
replacement mutagenesis. J. Bacteriol. , 183, 1259-1268.
Chang, C. and Swaan, P. W. (2005). Computational approaches to modeling drug
transporters. Eur. J. Pharm. Sci., 27, 411-424.
Chang, C., Bahadduri, P. M., Polli, J. E., Swaan, P. W. and Ekins, S. (2006a).
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab.
Dispos., 34, 1976-1984.
Chang, C., Ekins, S., Bahadduri, P. and Swaan, P. W. (2006b).
Pharmacophorebased discovery of ligands for drug transporters. Adv. Drug
Del. Rev., 58, 1431-1450.
Chen, Y. Z. and Ung, C. Y. (2001). Prediction of potential toxicity and side effect
protein targets of a small molecule by a ligand-protein inverse docking
approach. J. Mol. Graph. Model., 20, 199-218.

Bibliography
_________________________________________________________________________
158
Chen, Y. Z. and Zhi, D. G. (2001). Ligand-protein inverse docking and its potential
use in the computer search of protein targets of a small molecule. Proteins,
43, 217-226.
Choi, V. (2005). YUCCA, an efficient algorithm for small-molecule docking. Chem.
Biodivers., 2, 1517-1524.
Christman, M. F., Morgan, R. W., Jacobson, F. S. and Ames, B. N. (1985). Cell,
41, 753-762
Clements, J. M., Beckett, R. P., Brown, A., Catlin, G., Lobell, M., Palan, S.,
Thomas, W., Whittaker, M., Wood, S., Salama, S., Baker, P. J., Rodgers, H.
F., Barynin, V., Rice, D. W., and Hunter, M. G. (2001). Antimicrob. Agents
Chemother., 45, 563−570.
Colas, P. (1996). Genetic selection of peptide aptamers that recognize and inhibit
cyclin-dependent kinase 2. Nature, 380, 548-550.
Connors, T. A. (1984). Antitumour Drug Resistance (Fox, B. W. and Fox, M., eds.),
pp. 403-422, Springer-Verlag, Berlin, Heidelberg, New York, Tokyo.
Cummings, M. D., DesJarlais, R. L., Gibbs, A. C., Mohan, V. and Jaeger, E. P.
(2005). Comparison of automated docking programs as virtual screening
tools. J. Med. Chem., 48(4), 962-976. [PubMed, 15715466].
Cundliffe, E. (1984). Br. Med. Bull., 40, 61-67.

Bibliography
_________________________________________________________________________
159
Dajani, R., Cleasby, A., Neu, M., Wonacott, A. J., Jhoti, H. and Hood, A. M.
(1999). X-ray crystal structure of human dopamine sulfotransferase,
SULT1A3. J. Biol. Chem., 53, 37862-37868.
Danchin, A., Medigue, C., Gascuel, O., Soldano, H. and Henaut, A. (1991). From
data banks to data bases. Res. Microbiol., 142, 913-916.
Davie, E. W. (1991). Biochemistry, 30, 10363. [PMID, 1931959].
Davie, E. W. (1991). Biochemistry, 30, 10363. [PMID, 1931959].
Davis, A. M. (2003). Angew. Chem. Int. Ed., 42, 2718. [PMID, 12820253].
De Graaf, C., Vermeulen, N. P. and Feenstra, K. A. (2005). Cytochrome P450 in
silico, an integrative modeling approach. J. Med. Chem., 48, 2725-2755.
De Groot, M. J. and Ekins, S. (2002). Pharmacophore modeling of cytochromes
P450. Adv. Drug. Del. Rev., 54, 367-383.
De, Groot, M. J. (2006). Designing better drugs, predicting cytochrome P450
metabolism. Drug Discov. Today, 11, 601-606.
Deisenhofer, J. and Smith, J. L. (2001). Curr. Opin. Struc. Bio., 11, 701.
Demple, B., Sedgwick, B., Robins, P., Totty, N., Waterfield, M. D. and Lindahl, T.
(1985). Proc. Natl. Acad. Sci. U. S. A., 82, 2688-2692.
Di Masi, J. A. (2002). The value of improving the productivity of the drug
development process. Pharmacoeconomics, 20 (Suppl. 3), 1-10.

Bibliography
_________________________________________________________________________
160
Di Santo, R., Fermeglia, M., Ferrone, M., Paneni, M. S., Costi, R. and Artico, M.
(2005). Simple but highly effective three-dimensional chemical-feature-
based pharmacophore model for diketo acid derivatives as hepatitis C virus
RNA-dependent RNA polymerase inhibitors. J. Med. Chem., 48, 6304-6314.
Dooley, A. J., Shindo, N., Taggart, B., Park, J. G. and Pang, Y. P. (2006). From
genome to drug lead, identification of a small-molecule inhibitor of the
SARS virus. Bioorg. Med. Chem. Lett., 16, 830-833.
Drews, J. (2000). Drug discovery, a historical perspective. Science. 17, 287(5460),
1960-1964.
Drews, J. (2000). Science, 287, 1960. [PMID, 10720314].
Ecker, D. J. and Griffey, R. H. (1999). Drug Discovery Today, 4, 420. [PMID,
10461152].
Edwards, S., Zhu, J. and Caurie, C. (2005). Integrating QTL and high-density SNP
analyses in mice to identify Insig2 as a susceptibility gene for plasma
cholesterol levels. Genomics, 86, 505-517.
Ekins, S., Bravi, G., Binkley, S., Gillespie, J. S., Ring, B. J. and Wikel, J. H.
(1999). Three and four dimensional-quantitative structure activity
relationship analyses of CYP3A4 inhibitors. J. Pharmacol. Exp. Ther., 290,
429-438.

Bibliography
_________________________________________________________________________
161
Ekroos, M. and Sjogren, T. (2006). Structural basis for ligand promiscuity in
cytochrome P450 3A4. Proc. Natl. Acad. Sci. USA, 103, 13682-13687.
Enyedy, I. (2001). J. Med. Chem., 44, 1349. [PMID, 11311057].
Enyedy, I. (2001). J. Med. Chem., 44, 4313. [PMID, 11728179].
Evers, A. and Klebe, G. (2004). Successful virtual screening for a submicromolar
antagonist of the neurokinin-1 receptor based on a ligand-supported
homology model. J. Med. Chem., 47, 5381-5392.
Evers, A., Gohlke, H. and Klebe, G. (2003). Ligand-supported homology modelling
of protein binding-sites using knowledge-based potentials. J. Mol. Biol., 334,
327-345.
Evers, A. and Klabunde, T. (2005). Structure-based drug discovery using GPCR
homology modeling, successful virtual screening for antagonists of the
alpha1A adrenergic receptor. J. Med. Chem., 48,1088-1097.
Ewing, T. J., Makino, S., Skillman, A. G. and Kuntz, I. D. (2001). DOCK 4. 0,
search strategies for automated molecular docking of flexible molecule
databases. J. Comput. Aided Mol. Des., 15, 411-428.
Flohr, S., Kurz, M., Kostenis, E., Brkovich, A., Fournier, A. and Klabunde, T.
(2002). J. Med. Chem., 45, 1799-1805.
Frantz, S. and Smith, A. (2003). New drug approvals for 2002. Nat. Rev. Drug.
Discov., 2, 95-96.

Bibliography
_________________________________________________________________________
162
Freiberg, C. (2001). Novel computational methods in anti-microbial target
identification. Drug Discov. Today, 6, S72-S80.
Freiberg, C., Wieland, B., Spaltmann, F., Ehlert, K., Brotz, H. and Labischinski, H.
(2001). Identification of novel essential Escherichia coli genes conserved
among pathogenic bacteria. J. Mol. Microbiol. Biotechnol., 3, 483-489.
Frosch, M. and Reidl, J. (1998). Genomics in infectious diseases, approaching the
pathogens. Trends in Microbiology., 6 (9), 346-349.
Gallo, Robert, C. (1990). Journal of Acquired Immune Deficiency Syndromes.
Lippincott Williams and Wilkins, WK Health.
Galperin, M. Y. and Koonin, E. V. (1999). Searching for drug targets in microbial
genomes. Current Opinion in Biotechnology, 10, 571-578.
Gamage, N. U., Duggleby, R. G., Barnett, A. C., Tresillian, M., Latham, C. F. and
Liyou, N. E. (2003). Structure of a human carcinogenconverting enzyme,
SULT1A1. J. Biol. Chem., 278, 7655-7662.
Gerstein, M. (2000). Integrative database analysis in structural genomics. Nature,
Structural Biology Sup., 960-963.
Gerstein, M. and Jansen, R. (2000). The current excitement in bioinformatics -
analysis of whole-genome expression data, how does it relate to protein
structure and function? Current Opinion in Structural Biology, 10, 574-584.
Ghosh, S. (2001). Curr. Cancer Drug Targets, 1, 129. [PMID, 12188886].

Bibliography
_________________________________________________________________________
163
Glen, R. C. (1995). J. Med. Chem., 38, 3566. [PMID, 7658443].
Goodford, P. J. (1980). Br. J. Pharmacol., 68, 741. [PMID, 7378645].
Gopalakrishnan, B., Aparna, V., Jeevan, J., Ravi, M. and Desiraju, G. R. (2005).
A virtual screening approach for thymidine monophosphate kinase inhibitors
as antitubercular agents based on docking and pharmacophore models.
J. Chem. Inf. Model, 45, 1101-1108.
Grabowski, H., Vernon, J. and DiMasi, J. A. (2002). Returns on research and
development for 1990s new drug introductions. Pharmacoeconomics,
20 (Suppl. 3), 11-29.
Grant, S. F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R. and Manolescu, A.
(2006). Variant of transcription factor 7-like 2 (TCF7L2). gene confers risk of
type 2 diabetes. Nat Genet, 38, 320-323.
Gray, N. S. (1998). Exploiting chemical libraries, structure and genomics in the
search for kinase inhibitors. Science, 281, 533-538.
Greer, J. (1994). J. Med. Chem., 37, 1035. [PMID, 8164249].
Grigoriev, I. V. and Kim, S-H. (1999). Detection of protein fold similarity based on
correlation of amino acid properties. Proc. Natl. Acad. Sci. USA., 96, 14318-
14323.
Grzybowski, B. A., Ishchenko, A. V., Kim, C-K., Topalov, G., Chapman, R. and
Christianson, D. W. (2002). Combinatorial computational method gives new

Bibliography
_________________________________________________________________________
164
picomolar ligands for a known enzyme. Proc. Natl. Acad. Sci. USA, 99,
1270-1273.
Haines, J. L., Hauser, M. A., Schnidt, S., Scott, W. K. and Olson, L. M. (2005).
Complement factor H variant increases the risk of age-related macular
degeneration. Science, 308, 419-421.
Hajduk, P. J., Huth, J. R. and Tse, C. (2005). Predicting protein druggability. Drug
Discov. Today, 10, 1675-1682.
Hamer, L., DeZwaan, T. M., Montenegro-Chamorro, M. V., Frank, S. A. and
Hamer, J. E. (2001). Recent advances in large-scale transposon
mutagenesis. Curr. Opin. Chem. Biol., 5, 67-73.
Hansch, C., Lien, E. J. and Helmer, F. (1968). Structure-activity correlations in the
metabolism of drugs. Arch. Biochem. Biophys., 128, 319-330.
Haq, I. (2002). Arch. Biochem Biophys., 403, 1. [PMID, 12061796].
Hardy, L. W. and Malikayil, A. (2003). Curr. Drug Discov., 15.
Hare, R. S., Walker, S. S., Dorman, T. E., Greene, J. R., Guzman, L. M., Kenney,
T. J., Sulavik, M. C., Baradaran, K., Houseweart, C., Yu, H. Y., Foldes
Motzer, Z., Walbridge, M., Shimer, G. H. and Shaw, K. J. (2001). Genetic
footprinting in bacteria. J. Bacteriol., 183, 1694-1706.
Heinemann, J. A. (1999). How antibiotics cause antibiotic resistance. Drug
Discovery Today, 4, 72-79.

Bibliography
_________________________________________________________________________
165
Herbert, A., Gerry, N. P., McQueen, M. B., Heid, I. M. and Pfeufer, A. (2006). A
common genetic variant is associated with adult and childhood obesity.
Science, 312, 279-283.
Hinton, J. C. D. (1997). The Escherichia coli genome sequence, The end of an era
or the start of the FUN? Mol. Microbiol., 26, 417-422
Holm, L. and Sander, C. (1993). Protein structure comparison by alignment of
distance matrices. Journal of Molecular Biology, 233, 123-138.
Honglin Li, Zhenting Gao, Ling Kang, Hailei Zhang, Kun Yang, Kunqian Yu,
Xiaomin Luo, Weiliang Zhu, Kaixian Chen, Jianhua Shen, Xicheng Wang,
and Hualiang Jiang (2006). TarFisDock, a web server for identifying drug
targets with docking approach. Nucleic Acids Research, Vol. 34, Web
Server issue W219-W224.
Hood, D. W. (1999). The utility of complete genome sequences in the study of
pathogenic bacteria. Parasitology, 118, S3-S9.
Hopkins, A. L. and Groom, C. R. (2002). The druggable genome. Nature Rev.
Drug Discov., 1, 727-730.
Horn, F., Weare, J., Beukers, M. W., Horsch, S. and Bairoch, A. (1998). GPCRDB,
An information system for G protein-coupled receptors. Nucleic Acids Res.,
26, 275-279.

Bibliography
_________________________________________________________________________
166
Huang, C. M., Elmets, C. A., Tang, D. C., Li, F. and Yusuf, N. (2004). Proteomics
reveals that proteins expressed during the early stage of Bacillus anthracis
infection are potential targets for the development of vaccines and drugs.
Genomics Proteomics Bioinformatics, 2, 143-151.
Huang, J. and Schreiber, S. L. (1997). A yeast genetic system for selecting small
molecule inhibitors of protein-protein interactions in nanodroplets. Proc.
Natl. Acad. Sci. USA, 94, 13396-13401.
Hutchison, C. A., Peterson, S. N., Gill, S. R., Cline, R. T., White, O., Fraser, C. M.,
Smith, H. O. and Venter, J. C. (1999). Global transposon mutagenesis and
a minimal mycoplasma genome. Science, 286, 2165-2169.
Huynen, M. A. (1997). Trends Genet., 13, 389. [PMID, 9351339].
Itaya, M. (1995). An estimation of minimal genome size required for life. FEBS
Lett., 362, 257-260.
Jenkins, J. L., Kao, R. Y. and Shapiro, R. (2003). Proteins, 50, 81-93.
Jenks, P. J., Chevalier, C., Ecobichon, C. and Labigne, A. (2001). Identification of
nonessential Helicobacter pylori genes using random mutagenesis and loop
amplification. Res. Microbiol., 152, 725-734.
Ji, Z. L., Wang, Y., Yu, L., Han, L. Y., Zheng, C. J. and Chen, Y. Z. (2006). In silico
search of putative adverse drug reaction related proteins as a potential tool
for facilitating drug adverse effect prediction. Toxicol. Lett., 164, 104-112.

Bibliography
_________________________________________________________________________
167
John D. Hayes and Roland Wolf, C. (1990). Molecular mechanisms of drug
resistance. Biochem. J., 272, 281-295 (Printed in Great Britain).
John Edwards (1981) http, //www. newdrugdesign. com/Rachel_Theory_04. html
Johnson, A. P. (2001). Curr. Opin. Investig. Drugs, 12, 1691−1701.
Jones, G., Willett, P., Glen, R. C., Leach, A. R. and Taylor, R. (1997).
Development and validation of a genetic algorithm for flexible docking. J.
Mol. Biol., 267, 727-748.
Jouanguy, E. (1999). A human IFNGR1 small deletion hotspot associated with
dominant susceptibility to mycobacterial infection. Nat. Genet., 21, 370-378.
Judson, N. and Mekalanos, J. J. (2000). TnAraOut, a transposon-based approach
to identify and characterize essential bacterial genes. Nat. Biotechnol., 18,
740-745.
Judson, N. and Mekalanos, J. J. (2000). Transposon-based approaches to identify
essential bacterial genes. Trends Microbiol., 8, 521-526.
Kalman, S. (1999). Comparative genomes of Chlamydia pneumoniae and C.
trachomatis. Nat. Genet., 21, 385-389.
Kang, J., Wang, L., Chen, X-L., Triggle, D. J. and Rampe, D. (2001). Interactions
of a series of fluoroquinolone antibacterial drugs with the human cardiac Kþ
channel HERG. Mol. Pharmacol., 59, 122-126.

Bibliography
_________________________________________________________________________
168
Karp, C. L., Grupe, A., Schadt, E., Ewert, S. L. and Keane-Moore, M. (2000).
Identification of complement factor 5 as a susceptibility locus for
experimental allergic asthma. Nat Immunol, 1, 221-226
Karp, P. D. (1999). Integrated pathway-genome databases and their role in drug
discovery. Trends Biotechnol., 17, 275-281.
Kawakami, Y. (1996). Bioorg. Med. Chem., 4, 1429. [PMID, 8894101].
Keenan, R. M. (1993). J. Med. Chem., 36, 1880. [PMID, 8515425].
Kellenberger, E., Rodrigo, J., Muller, P. and Rognan, D. (2004). Comparative
evaluation of eight docking tools for docking and virtual screening accuracy.
Proteins, 57, 225-242.
Kenyon, V., Chorny, I., Carvajal, W. J., Holman, T. R. and Jacobson, M. P. (2006).
Novel human lipoxygenase inhibitors discovered using virtual screening
with homology models. J. Med. Chem., 49, 1356-1363.
Kitchen, D. B., Decornez, H., Furr, J. R. and Bajorath, J. (2004). Docking and
scoring in virtual screening for drug discovery, methods and applications.
Nat. Rev. Drug. Discov., 3(11),935-949. [PubMed,15520816]
Klabunde, T. and Hessler, G. (2002). Chem. Bio. Chem., 3, 928-944.
Klebe, G. (2000). J Mol Med., 78, 269. [PMID, 10954199].
Klebe, G. (2006). Virtual ligand screening, strategies, perspectives and limitations.
Drug Discovery Today, 11(13-14),580-594. [PubMed, 16793526]

Bibliography
_________________________________________________________________________
169
Klein, R. J., Zeis, C., Chew, E. Y., Tsai, J. Y. and Sackler, R. S. (2005).
Complement factor H polymorphism in age-related macular degeneration.
Science, 308, 385-389.
Kobayashi, K., Ehrlich, S. D., Albertini, A., Amati, G., Andersen, K. K., Arnaud, M.,
Asai, K., Ashikaga, S., Aymerich, S. and Bessieres, P. (2003). Essential
Bacillus subtilis genes. Proc. Natl Acad. Sci. USA, 100, 4678-4683.
Koga, A. (1980). J. Med. Chem., 23, 1358 (1980).
Kolonin, M. G. and Finley, R. L. (1998). Targeting cyclin-dependent kinases in
Drosophila with peptide aptamers. Proc. Natl. Acad. Sci. USA, 95, 14266-
14271.
Kotra, L. P., Vakulenko, S. and Mobashery, S. (2000). From genes to sequences
to antibiotics, prospects for future developments from microbial genomics.
2, 651-658.
Kuntz, I. D. (1992). Science, 257, 1078. [PMID, 1509259].
Langer, T., Eder, M., Hoffmann, R. D., Chiba, P. and Ecker, G. F. (2004). Lead
identification for modulators of multidrug resistance based on in silico
screening with a pharmacophoric feature model. Arch Pharm (Weinheim),
337, 317-327.
Lapatto, R. (1989). Nature, 342, 299. [PMID, 2682266].

Bibliography
_________________________________________________________________________
170
Lautenbach, E. and Polk, R. E. (2007). Resistant gram-negative bacilli, A
neglected healthcare crisis? Am. J. Health Syst. Pharm., 1, 64 (23 Suppl
14), S3-21; quiz S22-4.
Lewis, D. F. V. (2000). On the recognition of mammalian microsomal cytochrome
P450 substrates and their characteristics. Biochem. Pharmacol., 60, 293-
306.
Ley, A. B. (1958). Science, 127, 1118.
Li, H., Li, C., Gui, C., Luo, X., Chen, K., Shen, J., Wang, X. and Jiang, H. (2004).
GAsDock, a new approach for rapid flexible docking based on an improved
multi-population genetic algorithm. Bioorg. Med. Chem. Lett., 14, 4671-
4676.
Lill, M. A., Dobler, M. and Vedani, A. (2006). Prediction of small-molecule binding
to cytochrome P450 3A4, flexible docking combined with multidimensional
QSAR. Chem. Med. Chem., 6, 73-81.
Lindquist, S. (1986). Annu. Rev. Biochem., 55, 1151-1191.
Liu, Z., Huang, C., Fan, K., Wei, P., Chen, H. and Liu, S. (2005). Virtual screening
of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. J. Chem.
Inf. Model., 45, 10-17.

Bibliography
_________________________________________________________________________
171
Lloyd, D. G., Golfis, G., Knox, A. J. S., Fayne, D., Meegan, M. J. and Oprea, T. I.
(2006). Oncology exploration, chartering cancer medicinal chemistry space.
DDT, 11, 149-159.
Loferer, H. (2000). Mining bacterial genomes for antimicrobial targets. Molecular
Medicine Today, 6, 470-474.
Loferer, H., Jacobi, A., Posch, A., Gauss, C., Meier-Ewert, S. and Seizinger, B.
(2000). Integrated bacterial genomics for the discovery of novel
antimicrobials. Drug Discov. Today, 5, 107-114.
Lombardino, J. G. and Lowe III, J. A. (2004). The role of the medicinal chemist in
drug discovery - then and now. Nat. Rev. Drug Discov., 3, 853-862.
Lorenza Bordoli, Florian Kiefer, Konstantin Arnold, Pascal Benkert, James Battey,
and Torsten Schwede (2009). Protein structure homology modeling using
SWISS-MODEL workspace. Nature Protocols, 4, 1-13.
Lorenzen, S., Dunkel, M. and Preissner, R. (2005). In silico screening of drug
databases for TSE inhibitors. Biosystems, 80, 117-122.
Lu, I. L., Huang, C. F., Peng, Y. H., Lin, Y. T., Hsieh, H. P. and Chen, C. T.
(2006). Structure-based drug design of a novel family of PPARgamma
partial agonists, virtual screening, X-ray crystallography, and in vitro/in vivo
biological activities. J. Med. Chem., 49, 2703-2712.

Bibliography
_________________________________________________________________________
172
Luecke, H., Schobert, B., Richter, H. T., Cartailler, J. P. and Lanyi, J. K. (1999).
J. Mol. Biol., 291, 899-911.
Ma, P. and Zemmel, R. (2002). Value of novelty? Nat. Rev. Drug. Discov., 1(8),
571-572.
Mahajan, S. (1999). J. Biol. Chem., 274, 9587. [PMID, 10092645].
Maier, E. (1997). Automated array technologies for gene expression profiling.
Drug Discovery Today, 2, 315-324.
Mao, B., Gozalbes, R., Barbosa, F., Migeon, J., Merrick, S. and Kamm, K. (2006).
QSAR modeling of in vitro inhibition of cytochrome P450 3A4. J. Chem. Inf.
Model, 46, 2125-2134.
Maragakis, L. L., Perencevich, E.N. and Cosgrove, S. E. (2008). Clinical and
economic burden of antimicrobial resistance. Expert Rev. AntiInfect. Ther.
6, 751-63.
McGowan, J. E. Jr. (2006). Resistance in non-fermenting gram-negative bacteria,
multidrug resistance to the maximum. Am. J. Med., 119 (6 Suppl 1), 29-36.
Miesel, L., Greene, J. and Black, T. A. (2003). Genetic strategies for antibacterial
drug discovery. Nature Rev. Genet., 4, 442-456.
Mohan, V., Gibbs, A. C., Cummings, M. D., Jaeger, E. P. and DesJarlais, R. L.
(2005). Docking, successes and challenges. Curr. Pharm. Des., 11,
323-333.

Bibliography
_________________________________________________________________________
173
Moir, D. T., K. J. Shaw, R. S. Hare, and G. F. Vovis. (1999). Genomics and
antimicrobial drug discovery. Antimicrob. Agents Chemother., 43, 439-446.
Mootha, V. K., Lindgren, C. M., Eriksson, K. F., Subramanian, A. and Sihag, S.
(2003). PGC-1alpha-responsive genes involved in oxidative
phosphorylation are coordinately downregulated in human diabetes. Nat.
Genet., 34, 267-273.
Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K.
and Olson, A. J. (1998). Automated docking using a Lamarckian Genetic
Algorithm and an empirical binding Free Energy Function. J. Comput.
Chem., 19, 1639-1662.
Muegge, I. and Enyedy, I. J. (2004). Virtual screening for kinase targets. Curr.
Med. Chem., 11, 693-707.
Mushegian, A. R. and Koonin, E. V. (1996). A minimal gene set for cellular life
derived by comparison of complete bacterial genomes. Proc. Natl. Acad.
Sci. USA, 93, 10268-10273.
Myers, P. L. (1997). Will combinatorial chemistry deliver real medicines? Curr.
Opin. Biotechnol., 8, 701-707.
Nilsen, T. W. (2001). Method for identifying essential or functional genes. US
Patent, 6, 248, 525.

Bibliography
_________________________________________________________________________
174
Nisbet, L. J. and Moore, M. (1997). Will natural products remain an important
source of drug research for the future? Curr. Opin. Biotechnol., 8, 708-712.
Nuwaysir, E. F. (1999). Microarrays and toxicology, The advent of toxicogenomics.
Mol. Carcinog., 24, 153-159.
Oren M. Becker, Yael Marantz, Sharon Shacham, Boaz Inbal, Alexander Heifetz,
Ori Kalid, Shay Bar-Haim, Dora Warshaviak, Merav Fichman, and Silvia
Noiman (2004). G protein-coupled receptors, In silico drug discovery in 3D,
101, 11304-11309.
Ozdemir, V., Shear, N. H. and Kalow, W. (2001). What will be the role of
pharmacogenetics in evaluating drug safety and minimizing adverse
effects? Drug Safety, 24, 75-85.
Paige, L. A. (1999). Estrogen receptor (ER). modulators each induce distinct
conformational changes in ERa and ERb. Proc. Natl. Acad. Sci. USA, 96,
3999-4004.
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A.,
Trong, I. L., Teller, D. C., Okada, T. and Stenkamp, R. E. (2000). Science,
289, 739-745.
Palmer, L. M., Pratt, J. M. and Rosenberg, M. (2000). Method for determining
gene essentiality in a pathogen. US Patent, 6, 139, 817.

Bibliography
_________________________________________________________________________
175
Paolini, G. V., Shapland, R. H., Van Hoorn, W. P., Mason, J. S. and Hopkins, A. L.
(2006). Global mapping of pharmacological space. Nat. Biotechnol., 24,
805-815.
Paul, N., Kellenberger, E., Bret, G., Muller, P. and Rognan, D. (2004). Recovering
the true targets of specific ligands by virtual screening of the protein data
bank. Proteins, 54, 671-680.
Peacock, M. L., Warren, J. T. Jr, Roses, A. D. and Fink, J. K. (1993). Novel
polymorphism in the A4 region of the amyloid precursor protein gene in a
patient without Alzheimer’s disease. Neurology, 43, 1254-1256.
Pebay-Peyroula, E., Rummel, G., Rosenbusch, J. P. and Landau, E. M. (1997).
Science, 277, 1676-1681.
Pellecchia, M. (2002). Nat. Rev. Drug Discov., 1, 211. [PMID, 12120505].
Pleban, K., Kaiser, D., Kopp, S., Peer, M., Chiba, P. and Ecker, G. F. (2005).
Targeting drug-efflux pumps - a pharmacoinformatic approach. Acta.
Biochim. Pol., 52, 737-740.
Poroikov, V. V., Filimonov, D. A., Borodina, Y. V., Lagunin, A. A. and Kos, A.
(2000). Robustness of biological activity spectra predicting by computer
program PASS for non-congeneric sets of chemical compounds. J. Chem.
Inf. Comput Sci., 40, 1349–1355.

Bibliography
_________________________________________________________________________
176
Prentis, R. A., Lis, Y. and Walker, S. R. (1988). Pharmaceutical innovation by the
seven UK-owned pharmaceutical companies (1964-1985). Br J Clin
Pharmacol., 25, 387-96.
Projan, S. (2002). Curr. Opin. Pharmacol., 2, 513−522.
Rarey, M., Kramer, B., Lengauer, T. and Klebe, G. (1996). A fast flexible docking
method using an incremental construction algorithm. J. Mol. Biol., 261, 470-
489.
Rattner, A., Sun, H. and Nathans, J. (1999). Annu. Rev. Genet., 33, 89-131.
Reich, K. A., Chovan, L. and Hessler, P. (1999). Genome scanning in
Haemophilus influenzae for identification of essential genes. J. Bacteriol.,
181, 4961-4968.
Rockey, W. M. and Elcock, A. H. (2005). Rapid computational identification of the
targets of protein kinase inhibitors. J. Med. Chem., 48, 4138-4152.
Rodrigues, A. D. and Lin, J. H. (2001). Curr. Opin. Chem. Biol., 5, 396-401.
Rodrigues, A. D. and Rushmore, T. H. (2002). Cytochromep450
pharmacogenetics in drug development, in vitro studies and clinical
consequences. Curr. Drug. Metab., 3, 289-309.
Rollinger, J. M., Bodensieck, A., Seger, C., Ellmerer, E. P., Bauer, R. and Langer,
T. (2005). Discovering COX-inhibiting constituents of Morus root bark,
activity-guided versus computer-aided methods. Planta. Med., 71, 399-405.

Bibliography
_________________________________________________________________________
177
Rollinger, J. M., Hornick, A., Langer, T., Stuppner, H. and Prast, H. (2004).
Acetylcholinesterase inhibitory activity of scopolin and scopoletin
discovered by virtual screening of natural products. J. Med. Chem., 47,
6248-6254.
Rosamond, L. and Allsop, A. (2000). Harnessing the power of the genome in the
search for new antibiotics. Science, 287, 1973-1976.
Roses, A. D. (2000). Pharmacogenetics and the practice of medicine. Nature, 405,
857-65.
Roth, B. L., Lopez, E., Beischel, S., Westkaemper, R. B. and Evans, J. M. (2004).
Screening the receptorome to discover the molecular targets for plant-
derived psychoactive compounds, a novel approach for CNS drug
discovery. Pharmacol. Ther., 102, 99-110.
Rowland, P., Blaney, F. E., Smyth, M. G., Jones, J. J., Leydon, V. R., Oxbrow, A.
K. (2006). Crystal structure of human cytochrome P450 2D6. J. Biol. Chem.,
281, 7614-7622.
Sakharkar, K. R., Sakharkar, M. K. and Chow, V. T. K. (2004). A novel genomics
approach for the identification of drug targets in pathogens, with special
reference to Pseudomonas aeruginosa. In Silico Biol., 4, 28.
Sali, A. and Blundell, T. L. (1993).Comparative protein modelling by satisfaction of
spatial restraints. J. Mol. Biol., 234, 779-815.

Bibliography
_________________________________________________________________________
178
Samson, L. and Cairns, J. (1977). Nature (London). 267, 281-283.
Sandra Kraljevic, Peter J. Stambrook and Kresimir Pavelic (2004). Accelerating
drug discovery. EMBO Reports, 5, 837-842.
Sautel, M. and Milligan, G. (2000). Curr. Med. Chem., 7, 889-896.
Schadt, E. E. and Lum, P. Y. (2006). Reverse engineering gene networks to
identify key drivers of complex disease phenotypes. J. Lipid. Res., 47(12),
2601-2613.
Schadt, E. E., Monks, S. A., Drake, T. A., Lusis, A. J. and Che, N. (2003).
Genetics of gene expression surveyed in maize, mouse and man. Nature,
422, 297-302.
Schapira, M., Raaka, B. M., Samuels, H. H. and Abagyan, R. (2000). Rational
discovery of novel nuclear hormone receptor antagonists. Proc. Natl. Acad.
Sci. USA, 97, 1008-1013.
Schmid, M. B. (1989). Genetic analysis of temperature-sensitive lethal mutants of
Salmonella typhimurium. Genetics, 123, 625-633.
Schmid, M. B. (1998). Novel approaches to the discovery of antimicrobial agents.
Curr. Opin. Chem. Biol., 2, 529-534.
Schoneberg, T., Schulz, A. and Gudermann, T. (2002). Rev. Physiol. Biochem.
Pharmacol., 144, 143-227.

Bibliography
_________________________________________________________________________
179
Service, R. F. (1998). Microchip arrays put DNA on the spot. Science, 282, 396-
399.
Shacham, S., Marantz, Y., Bar-Haim, S., Kalid, O., Warshaviak, D., Avisar, N.,
Inbal, B., Heifetz, A., Fichman, M. and Topf, M. (2004). Proteins.
Shacham, S., Topf, M., Avisar, N., Glazer, F., Marantz, Y., Bar-Haim, S., Noiman,
S., Naor, Z. and Becker, O. M. (2001). Med. Res. Rev., 21, 472-483.
Shao, D., Berrodin, T. J., Manas, E., Hauze, D., Powers, R. and Bapat, A. (2004).
Identification of novel estrogen receptor alpha antagonists. J. Steroid.
Biochem. Mol. Biol., 88, 351-360.
Shen, J., Xu, X., Cheng, F., Liu, H., Luo, X., Shen, J., Chen, K., Zhao, W., Shen,
X. and Jiang, H. (2003). Virtual screening on natural products for
discovering active compounds and target information. Curr. Med. Chem.,
10, 2327-2342.
Shi, Y. (2006). Orphan nuclear receptors, excellent targets of drug discovery.
Comb. Chem. High. Throughput Screen, 9, 683-689.
Shoichet, B. K. (2004). Virtual screening of chemical libraries. Nature 432(7019),
862-865. [PubMed,15602552]
Sibanda, B. L. (1983). Nature, 304, 273. [PMID, 6346109].
Sieburg, H. B. (1990). Physiological studies in silico. Studies in the Sciences of
Complexity, 12, 321-342.

Bibliography
_________________________________________________________________________
180
Sladek, R., Rocheleau, G., Rung, J., Dina, C. and Shen, L. (2007). A genome-
wide association study identifies novel risk loci for type 2 diabetes. Nature,
445, 881-885.
Smider, V., Rathmell, W. K., Lieber, M. and Chu, G. (1994). Restoration of X-ray
resistance and V(D)J recombination in mutant cells by Ku cDNA. Science,
266, 288-291.
Smith, D. R. (1996). Microbial pathogen genomes - new strategies for identifying
therapeutics and vaccine targets. Trends Biotechnology, 8, 290-293.
Smith, V., Botstein, D. and Brown, P. O. (1995). Genetic footprinting, a genomic
strategy for determining a gene’s function given its sequence. Proc. Natl.
Acad. Sci. USA, 92, 6479-6483.
Smith, V., Chou, K. N., Lashkari, D., Botstein, D. and Brown, P. O. (1996).
Functional analysis of the genes of yeast chromosome V by genetic foot-
printing. Science, 274, 2069-2074.
Snodin, D. J. (2002). An EU perspective on the use of in vitro methods in
regulatory pharmaceutical toxicology. Toxicol. Lett., 127, 161-168.
Stark, G. R. (1986). Cancer Surveys, 5, 1-23.
Steindl, T. and Langer, T. (2004). Influenza virus neuraminidase inhibitors,
generation and comparison of structure-based and common feature

Bibliography
_________________________________________________________________________
181
pharmacophore hypotheses and their application in virtual screening.
J. Chem. Inf. Comput Sci., 44, 1849-1856.
Steindl, T. M., Crump, C. E., Hayden, F. G. and Langer, T. (2005a).
Pharmacophore modeling, docking, and principal component analysis
based clustering, combined computer-assisted approaches to identify new
inhibitors of the human rhinovirus coat protein. J. Med. Chem., 48, 6250-
6260.
Steindl, T., Laggner, C. and Langer, T. (2005b). Human rhinovirus 3C protease,
generation of pharmacophore models for peptidic and nonpeptidic inhibitors
and their application in virtual screening. J. Chem. Inf. Model, 45, 716-724.
Storz, G., Tartaglia, L. A. and Ames, B. N. (1990). Science, 248, 189-194.
Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey,
M. J., Brinkman, F. S., Hufnagle, W. O., Kowalik, D. J. and Lagrou, M.,
(2000). Nature, 406, 959−964.
Strachan, R. T., Ferrara, G. and Roth, B. L. (2006). Screening the receptorome, an
efficient approach for drug discovery and target validation. Drug Discov.
Today, 11, 708-716.
Sudbeck, E. A. (1999). Clin. Cancer Res., 5, 1569. [PMID, 10389946].
Swaan, P. W. and Ekins, S. (2005). Reengineering the pharmaceutical industry by
crash-testing molecules. Drug Disc. Today, 10, 1191-1200.

Bibliography
_________________________________________________________________________
182
Taccioli, G. E. (1994). Ku80, product of the XRCC5 gene and its role in DNA
repair and V(D)J recombination. Science, 265, 1442-1445.
Tatusov, R. L. (1997). A genomic perspective on protein families. Science, 278,
631-637.
Terlau, H. and Stuhmer, W. (1998). Structure and function of voltage-gated ion
channels. Naturwissenschaften, 85, 437-444.
Tesmer, J. J. G. (2006). Hitting the hot spots of cell signaling cascades. Science,
312, 377-378.
Testa, B. and Kraämer, S. D. (2006). The biochemistry of drug metabolism - an
introduction. Part 1, principles and overview. Chem. Biodivers., 3, 1053-
1101.
Timberlake, W. and Gavrias, V. (1999). Identification of essential survival genes.
US Patent, 5, 976, 828.
Tsuchida, K., Chaki, H., Takakura, T., Kotsubo, H., Tanaka, T. and Aikawa, Y.
(2006). Discovery of nonpeptidic small-molecule AP-1 inhibitors, lead
hopping based on a three-dimensional Pharmacophore model. J. Med.
Chem., 49, 80-91.
Van Dongen, M. J., Uppenberg, J., Svensson, S., Lundback, T., Akerud, T.,
Wikstrom, M. and Schultz, J. (2002). J. Am. Chem. Soc., 124, 11874-
11880.

Bibliography
_________________________________________________________________________
183
Van’t Veer, L. J., Dai, H., Van de Vijver, M. J. and He, Y. D. (2002). Gene
expression profiling predicts clinical outcome of breast cancer. Nature, 415,
530-536
Vankayalapati, H. (2003). Mol. Cancer Ther., 2, 283. [PMID, 12657723]
Varady, J., Wu, X., Fang, X., Min, J., Hu, Z., Levant, B. and Wang, S. (2003).
J. Med. Chem., 46, 4377-4392.
Varghese, J. N. (1999). Drug Dev. Res., 46, 176.
Veber, D. F. (1992). Peptides, Chemistry, and Biology. Proceedings of the 12th
American Peptide Symposium, eds. Smith, J. A. and Rivier, J. E. (ESCOM,
Leiden, The Netherlands), pp. 3-14.
Venter, J. C. (2001). Science, 291, 1304. [PMID, 11181995].
Vieth, M., Higgs, R. E., Robertson, D. H., Shapiro, M., Gragg, E. A. and
Hemmerle, H. (2004). Kinomics-structural biology and chemogenomics of
kinase inhibitors and targets. Biochim. Biophys. Acta., 1697, 243-257.
Walker, G. C. (1985). Annu. Rev. Biochem., 54, 425-457.
Walters, P. W. (1998). Drug Discovery Today, 3, 160.
Wang, R., Fang, X., Lu, Y. and Wang, S. (2004). The PDBBind
database,collection of binding affinities for protein–ligand complexes with
known three-dimensional structures. J. Med. Chem., 47, 2977–2980.

Bibliography
_________________________________________________________________________
184
Watson K. C., Jourbert, S. M., and Bennett, M. A. E. (1959). Nature (Lond. ), 183,
468.
Whittaker, P. A. (2003). What is the relevance of bioinformatics to pharmacology?
Trends Pharmacol. Sci., 24, 434-439.
Whittle, P. J. and Blundell, T. L. (1994). Protein structure based drug design.
Annu. Rev. Biophys. Biomol. Struct., 23, 349-375.
Wilson, M. (1999). Exploring drug-induced alterations in gene expression in
Mycobacterium tuberculosis by microarray hybridization. Proc. Natl. Acad.
Sci. USA, 96, 12833-12838.
Wilson, S. and Bergsma, D. (2000). Drug Des. Discovery, 17, 105-114.
Wise, A., Jupe, S. C. and Rees, S. (2004). The identification of ligands at orphan
G-protein coupled receptors. Annu. Rev. Pharmacol. Toxicol., 44, 43-66.
Wishart, D. S., Knox, C, Guo, A. C., Shrivastava, S., Hassanali, M. and Stothard,
P. (2006). DrugBank, a comprehensive resource for in silico drug discovery
and exploration. Nucleic Acids Res., 34, D668-D672.
Wlodawer, A. and Vondrasek, J. (1998). Annu. Rev. Biophys. Biomol. Struct., 27,
249. [PMID, 9646869].
Wolber, G. and Langer, T. (2005). LigandScout, 3-D pharmacophores derived
from protein-bound ligands and their use as virtual screening filters.
J. Chem. Inf. Model, 45, 160-169.

Bibliography
_________________________________________________________________________
185
Wong, B. R., Parlati, F., Qu, K., Demo, S., Pray, T. and Huang, J. (2003). Drug
discovery in the ubiquitin regulatory pathway. Drug Discov. Today, 8,
746-754.
Wong, S. M. and Mekalanos, J. J. (2000). Genetic footprinting with marinerbased
transposition in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA, 97,
10191-10196.
Wrighton, N. C. (1996). Small peptides as potent mimetics of the protein hormone
erythropoietin. Science, 273, 458-464.
Yu, J., Paine, M. J., Marechal, J. D., Kemp, C. A., Ward, C. J. and Brown, S.
(2006). In silico prediction of drug binding to CYP2D6, identification of a
new metabolite of metoclopramide. Drug Metab. Dispos., 34, 1386-1392.
Zhang, E. Y., Knipp, G. T., Ekins, S. and Swaan, P. W. (2002a). Structural biology
and function of solute transporters, implications for identifying and designing
substrates. Drug Metab. Rev., 34, 709-750.
Zhang, E. Y., Phelps, M. A., Cheng, C., Ekins, S. and Swaan, P. W. (2002b).
Modeling of active transport systems. Adv. Drug. Del. Rev., 54, 329-354.
Zhao, L. and Brinton, R. D. (2005). Structure-based virtual screening for plant-
based ERbeta-selective ligands as potential preventative therapy against
age-related neurodegenerative diseases. J. Med. Chem., 48, 3463-3466.

Bibliography
_________________________________________________________________________
186
Website
http,//www. archive. org/details/arsdigita_04_java
http,//www.chestjournal.org/content/79/4_Supplement/38S The Discovery of
Penicillin Br Med J., 1955 March 19; 1(4915), 711.
http,//www. java2s. com/
http,//www. javaworld. com/javaworld/jw-06-1999/jw-06-javamail. html
http,//www. sun. com
____
`

Bibliography for the Drug Target Identification from Microbial Genomes

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Andere mochten auch

Andere mochten auch (20)

Ähnlich wie Bibliography for the Drug Target Identification from Microbial Genomes

Ähnlich wie Bibliography for the Drug Target Identification from Microbial Genomes (20)

Mehr von Dr. Paulsharma Chakravarthy

Mehr von Dr. Paulsharma Chakravarthy (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Bibliography for the Drug Target Identification from Microbial Genomes